Biotech
Zymergen
Zymergen raises $130M Series C at $560M valuation
$130M
Total Raised
Series C
Latest Round
2013
Founded
500+
Employees
Emeryville, CA
1 min read
Quick Facts
Valuation
$560M
Latest Round Size
$130M
Latest Round Date
December 2018
Zymergen: Series C Funding Round
Zymergen has successfully raised $130M in Series C funding, reaching a valuation of $560M.
Company Overview
Bio-based materials and molecule development
Funding Details
The Series C round was led by SoftBank Vision Fund, with participation from Data Collective.
Company Information
- Headquarters: Emeryville, CA
- Founded: 2013
- Employees: 500+
- Category: Biotech
Investment
Zymergen plans to use the funds to accelerate product development, expand its team, and scale operations globally.
About the Investors
- SoftBank Vision Fund: Verified investor in Series C
- Data Collective: Verified investor in Series C
Key Investors
SoftBank Vision Fund
Lead Investor
Verified investor in Series C
Data Collective
Investor
Verified investor in Series C
About the Author
Editorial Team
Curated funding news from verified sources
Related Company Reports
Biotech
Orna Therapeutics
Orna Therapeutics Raises $251M Series B
Biotechnology company developing circular RNA therapeutics for cancer, genetic diseases, and infectious diseases
Emma Rodriguez
Oct 23, 2025
0 min readβ’$251M Series B
Biotech
Forge Biologics
Forge Biologics Raises $120M Series C
Gene therapy CDMO providing manufacturing and development services for AAV-based genetic medicines
Sarah Kim
Oct 23, 2025
0 min readβ’$120M Series C
Biotech
Vir Biotechnology
Vir Biotechnology Raises $250M
Clinical-stage immunology company developing treatments for infectious diseases including COVID-19, hepatitis B, and influenza
Sarah Kim
Oct 23, 2025
0 min readβ’$250M